AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX)
13.6 USD
+0.400 3.030%Sponsored Reports
Loading...
| Previous Close (in USD) | 13.2 |
|---|---|
| Change | +0.400 3.030% |
| 52 W H/L (in USD) | 18.605/4.200 |
| EBITDA (in USD) | -152.766M |
| PE Ratio | -- |
| Volume | 324083 |
| Diluted Eps TTM | -1.53 |
| Total Assets (in USD) | 332.645M |
|---|---|
| Total Liabilities (in USD) | 27.386M |
| Revenue TTM (in USD) | -0.665M |
| Cash (in USD) | 226.651M |
| Market Cap (in USD) | 1,942.134 M |
| Revenue Per Share TTM | -0.008 |
| Gross Profit TTM (in USD) | -90.404M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Employees: 136
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Joshua B. Cohen | Co-Founder, Co-CEO & Director | 1992 |
| 2. | Mr. Justin B. Klee | Co-Founder, Co-CEO & Director | 1991 |
| 3. | Mr. James M. Frates M.B.A. | Chief Financial Officer | 1967 |
| 4. | Ms. Margaret M. Olinger M.B.A | Global Head of Commercial & Chief Commercial Officer | 1965 |
| 5. | Mr. Tom Holmes | Chief Technical Operations Officer | NA |
| 6. | Ms. Gina M. Mazzariello | Chief Legal Officer & Gen. Counsel | 1971 |
| 7. | Ms. Shauna Horvath | Head of Global Marketing | NA |
| 8. | Ms. Debra L. Canner | Global Head of HR & CHRO | 1959 |
| 9. | Dr. Patrick D. Yeramian M.D., MBA, Ph.D. | Global Head of Clinical R&D and Chief Medical Officer | 1959 |
| 10. | Mr. Chris Aiello | Head of Canada & GM | NA |
Peers
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
ZTS
Zoetis Inc |
+3.740 4.820% | 79.93 | 40.180 | 30.960 | 10.675 | 17.597 | 11.271 | 26.180 |
|
MKKGY
Merck KGaA ADR |
+1.350 4.353% | 32.175 | 21.250 | 14.925 | 3.099 | 2.143 | 3.605 | 12.978 |
|
MKGAF
MERCK Kommanditgesellschaft auf Aktien |
0.000 0.000% | 153.91 | 21.730 | 14.948 | 3.159 | 2.147 | 3.562 | 12.822 |
|
GALDY
GALDERMA GROUP AG |
-0.600 1.466% | 40.85 | 74.210 | 41.667 | 8.636 | 5.553 | 9.151 | 42.220 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -144.689M | -302.136M | 54.297M | -197.601M | -87.931M |
| Minority Interest | - | - | - | - | - |
| Net Income | -144.735M | -301.743M | 49.271M | -198.375M | -87.879M |
| Selling General Administrative | 62.887M | 111.631M | 178.856M | 127.128M | 38.933M |
| Gross Profit | -0.525M | 45.215M | 355.345M | 19.237M | 0.285M |
| Reconciled Depreciation | 0.525M | 0.904M | 1.088M | 0.487M | 0.052M |
| Ebit | -144.689M | -291.88M | 38.802M | -201.828M | -82.74M |
| Ebitda | -144.164M | -290.976M | 39.89M | -201.341M | -82.688M |
| Depreciation And Amortization | 0.525M | 0.904M | 1.088M | 0.487M | 0.052M |
| Operating Income | -153.291M | -314.731M | 38.802M | -201.341M | -82.688M |
| Other Operating Expenses | 153.291M | 402.102M | 341.984M | 223.571M | 82.688M |
| Interest Expense | - | - | - | 4.291M | 0.036M |
| Tax Provision | 0.046M | -0.393M | 5.026M | 0.774M | - |
| Interest Income | 9.302M | 13.809M | 16.155M | 4.291M | 0.036M |
| Net Interest Income | 9.302M | 13.809M | 16.155M | 4.291M | 0.036M |
| Income Tax Expense | 0.046M | -0.393M | 5.026M | 0.774M | -0.052M |
| Total Revenue | 0M | 87.371M | 380.786M | 22.23M | 0.285M |
| Total Operating Expenses | 152.766M | 359.946M | 316.543M | 220.578M | 82.688M |
| Cost Of Revenue | 0.525M | 42.156M | 25.441M | 2.993M | - |
| Total Other Income Expense Net | 8.602M | 12.595M | 15.495M | 3.74M | -5.243M |
| Net Income From Continuing Ops | -144.735M | -301.743M | 49.271M | -198.375M | -87.931M |
| Net Income Applicable To Common Shares | - | - | - | -198.375M | -87.931M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 332.645M | 193.634M | 517.454M | 391.453M | 105.614M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 6.604M | 12.484M | 14.931M | 10.113M | 8.833M |
| Total Liab | 27.386M | 28.869M | 84.022M | 50.846M | 256.782M |
| Total Stockholder Equity | 305.259M | 164.765M | 433.432M | 340.607M | -151.168M |
| Other Current Liab | 17.91M | 23.949M | 57.724M | -2.04M | 13.024M |
| Common Stock | 0.011M | 0.007M | 0.007M | 0.007M | 0.001M |
| Capital Stock | 0.011M | 0.007M | 0.007M | 0.007M | 0.001M |
| Retained Earnings | -751.427M | -606.692M | -304.949M | -354.22M | -155.845M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | - | 1.185M | 0.189M |
| Cash | 226.651M | 77.391M | 170.201M | 346.945M | 96.118M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 22.688M | 28.406M | 82.042M | 46.609M | 17.396M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | -220.694M | -75.41M | -165.964M | -340.668M | -96.118M |
| Short Term Debt | 1.259M | 1.518M | 2.257M | 2.04M | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 5.957M | 1.981M | 4.237M | 6.277M | - |
| Other Stockholder Equity | 1056.271M | 771.542M | 220.723M | 303.453M | -3.008M |
| Property Plant Equipment | - | - | - | 2.611M | 0.474M |
| Total Current Assets | 323.671M | 189.432M | 464.666M | 382.133M | 101.51M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 90.328M | 99.11M | 201.161M | 284.419M | 45.927M |
| Net Receivables | 0.088M | 0.447M | 40.05M | 15.306M | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | 0M | 38.323M | 9.769M | - |
| Accounts Payable | 3.519M | 2.939M | 22.061M | 46.609M | 17.396M |
| Accumulated Other Comprehensive Income | 0.404M | -0.092M | 0.197M | -0.086M | 0.009M |
| Non Currrent Assets Other | 3.483M | 1.47M | 45.658M | 1.185M | 3.63M |
| Non Current Assets Total | 8.974M | 4.202M | 52.788M | 9.32M | 4.104M |
| Capital Lease Obligations | 5.957M | 1.981M | 4.237M | 6.277M | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | 14.177M | 75.654M | -157.052M | -236.462M | -46.406M |
| Total Cashflows From Investing Activities | 14.039M | 75.654M | 92.053M | -238.988M | -46.406M |
| Total Cash From Financing Activities | 257.029M | 0.348M | 3.543M | 431.789M | 158.506M |
| Net Income | -144.735M | -301.743M | 49.271M | -198.375M | -87.931M |
| Change In Cash | 148.799M | -92.083M | 107.675M | 12.865M | 37.314M |
| Begin Period Cash Flow | 78.837M | 170.92M | 62.526M | 50.38M | 13.066M |
| End Period Cash Flow | 227.636M | 78.837M | 170.201M | 63.245M | 50.38M |
| Total Cash From Operating Activities | -123.343M | -167.647M | 11.919M | -179.871M | -74.799M |
| Depreciation | 0.525M | 0.904M | 1.088M | 0.487M | 0.052M |
| Other Cashflows From Investing Activities | - | -36.203M | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | 0M | -9.253M | -73.129M | -9.769M | -9.769M |
| Sale Purchase Of Stock | - | - | -3.315M | 434.636M | - |
| Other Cashflows From Financing Activities | -3.361M | -1.784M | -3.315M | -0.658M | 23.769M |
| Capital Expenditures | 0.138M | 0.157M | 1.241M | 2.526M | 0.353M |
| Change In Working Capital | -1.083M | -45.831M | -65.661M | -1.641M | 4.595M |
| Other Non Cash Items | -5.695M | 145.985M | -9.94M | -2.056M | 5.228M |
| Free Cash Flow | -123.481M | -167.804M | 10.678M | -182.397M | -75.152M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 3103915 |
| 2. | Fidelity Advisor Biotechnology I | 3 months ago | 2433200 |
| 3. | iShares Russell 2000 ETF | 2 months ago | 2210828 |
| 4. | Fidelity Small Cap Growth | 4 months ago | 2115961 |
| 5. | Eventide Healthcare & Life Sciences I | 5 months ago | 1512444 |
| 6. | Fidelity Select Health Care | 3 months ago | 1420000 |
| 7. | Xtrackers S&P 500 Swap ETF 1C | 5 months ago | 1240007 |
| 8. | Fidelity Select Biotechnology | 3 months ago | 1219575 |
| 9. | Strategic Advisers Fidelity US TtlStk | 3 months ago | 1138109 |
| 10. | Fidelity Stock Selector Small Cap | 4 months ago | 1085800 |
| 11. | Fidelity Small Cap Growth K6 | 4 months ago | 1053389 |
| 12. | Franklin Biotechnology Discv A(acc)USD | 2 months ago | 1028074 |
| 13. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 932126 |
| 14. | Fidelity Series Small Cap Opps | 4 months ago | 881400 |
| 15. | Fidelity Balanced | 4 months ago | 879837 |
| 16. | Fidelity Small Cap Index | 4 months ago | 859148 |
| 17. | Janus Henderson Hrzn Biotec E2 USD | 5 months ago | 806916 |
| 18. | Fidelity Advisor Health Care I | 3 months ago | 715000 |
| 19. | iShares Biotechnology ETF | 2 months ago | 688966 |
| 20. | Franklin Biotechnology Discovery A | 2 months ago | 600020 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | First Light Asset Management, LLC | 5 months ago | 3355539 |
| 2. | FMR Inc | 5 months ago | 16518419 |
| 3. | Perceptive Advisors LLC | 8 months ago | 8952365 |
| 4. | BlackRock Inc | 8 months ago | 7140692 |
| 5. | TCG Crossover Management, LLC | 5 months ago | 6243812 |
| 6. | Vanguard Group Inc | 5 months ago | 5804912 |
| 7. | COMMODORE CAPITAL LP | 5 months ago | 5650000 |
| 8. | Saturn V Capital Management LLC | 5 months ago | 4496487 |
| 9. | Driehaus Capital Management LLC | 5 months ago | 3109503 |
| 10. | Adage Capital Partners Gp LLC | 5 months ago | 2777055 |
| 11. | The Goldman Sachs Group Inc | 5 months ago | 2613221 |
| 12. | HHG PLC | 8 months ago | 2536233 |
| 13. | Geode Capital Management, LLC | 5 months ago | 2165534 |
| 14. | Almitas Capital LLC | 5 months ago | 2122597 |
| 15. | Morgan Stanley - Brokerage Accounts | 8 months ago | 1950301 |
| 16. | Great Point Partners LLC | 5 months ago | 1750000 |
| 17. | 683 Capital Management LLC | 5 months ago | 1650000 |
| 18. | State Street Corp | 8 months ago | 1621260 |
| 19. | Eventide Asset Management, LLC | 5 months ago | 1513148 |
| 20. | UBS Group AG | 8 months ago | 1404471 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...